{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:18:56Z","timestamp":1785352736663,"version":"3.55.0"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>To evaluate the performance of a circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) liquid biopsy, LiquidHALLMARK (LHM), compared with tissue next-generation sequencing (NGS) and Guardant360 CDx (G360 ctDNA) liquid biopsy for biomarker detection in metastatic nonsquamous non\u2013small cell lung cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS<\/jats:title>\n            <jats:p>\n              This multicenter, prospective study (ClinicalTrials.gov identifier:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04703153\">NCT04703153<\/jats:ext-link>\n              ) enrolled patients across the United States and Singapore. Patients were tested with tissue NGS, LHM, and G360 ctDNA. The primary objective was noninferiority of LHM ctDNA to tissue NGS and G360 ctDNA. Secondary analyses included turnaround time (TAT), overall response rate (ORR), and progression-free survival (PFS), with exploratory analysis of the clinical utility of ctRNA.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              LHM ctDNA (48.2%) detected 11.4% fewer biomarker-positive patients than tissue NGS (59.6%) and did not meet noninferiority criteria. Compared with tissue NGS, LHM ctDNA and G360 ctDNA were concordant in 72.1% and 66.1% of patients, establishing noninferiority of LHM ctDNA to G360 ctDNA (\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = .002). TAT was shorter for LHM ctDNA than for tissue NGS (mean 9.7\n              <jats:italic toggle=\"yes\">v<\/jats:italic>\n              21.7 days;\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt; .001). ORR\/PFS was similar in patients receiving targeted therapy based on all three assays. Addition of ctRNA increased the diagnostic yield of tissue NGS\u2013confirmed gene rearrangements by 28.6% relative to LHM ctDNA and all actionable biomarkers by 15.6% relative to G360 ctDNA. LHM ctDNA and ctRNA (51\/68) detected 8.8% more biomarker-positive patients than G360 ctDNA (45\/68), demonstrating superiority of LHM ctDNA and ctRNA (\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = .001).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>LHM ctDNA is noninferior to G360 ctDNA, but not tissue NGS. Treatment outcomes based on liquid biopsy are comparable with those based on tissue NGS. Incorporation of ctRNA into LHM ctDNA improves the diagnostic yield of actionable, tissue NGS\u2013confirmed gene rearrangements.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/po-25-00181","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:59:10Z","timestamp":1750967950000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":10,"title":["Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non\u2013Small Cell Lung Cancer (LIQUIK)"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-3528","authenticated-orcid":true,"given":"Jens","family":"Samol","sequence":"first","affiliation":[{"name":"Medical Oncology, Tan Tock Seng Hospital, Singapore"},{"name":"John Hopkins University, Baltimore, MD"},{"name":"Lee Kong Chian\/NTU, School of Medicine, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ng","sequence":"additional","affiliation":[{"name":"Medical Oncology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-8667","authenticated-orcid":true,"given":"Jonathan","family":"Poh","sequence":"additional","affiliation":[{"name":"Lucence Diagnostics Pte Ltd, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Han","family":"Tan","sequence":"additional","affiliation":[{"name":"Lucence Health Inc, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-1263","authenticated-orcid":true,"given":"Richa","family":"Dawar","sequence":"additional","affiliation":[{"name":"University of Miami Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Carney","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, HI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6642-2823","authenticated-orcid":true,"suffix":"Jr","given":"James","family":"Orsini","sequence":"additional","affiliation":[{"name":"New Jersey Cancer Care, Belleville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7904-8119","authenticated-orcid":true,"given":"Katherine","family":"Scilla","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yew Oo","family":"Tan","sequence":"additional","affiliation":[{"name":"Icon Cancer Centre, Farrer Park, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan Min","family":"Chin","sequence":"additional","affiliation":[{"name":"Parkway Cancer Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-6144","authenticated-orcid":true,"given":"Chee Keong","family":"Toh","sequence":"additional","affiliation":[{"name":"Curie Oncology, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4107-102X","authenticated-orcid":true,"given":"Boon Cher","family":"Goh","sequence":"additional","affiliation":[{"name":"National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-9903","authenticated-orcid":false,"given":"Gilberto","family":"Lopes","sequence":"additional","affiliation":[{"name":"University of Miami Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-0221"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00881-7"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0388-CP"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0025"},{"key":"e_1_3_6_7_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)\u2014Non-Small Cell Lung Cancer Version 3.2025","author":"National Comprehensive Cancer Network","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)\u2014Non-Small Cell Lung Cancer Version 3.2025. https:\/\/www.nccn.org"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.017"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32875"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.01.32"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01351-y"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa164"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267389"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3040"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3831"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015151516"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0624"},{"key":"e_1_3_6_18_2","article-title":"Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non\u2013small-cell lung cancer","author":"Palmero R","unstructured":"Palmero R, Taus A, Viteri S, et al: Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non\u2013small-cell lung cancer. JCO Precis Oncol 10.1200\/PO.20.00241","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103109"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1749"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33571"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0408-9"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0225"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.019"},{"key":"e_1_3_6_25_2","first-page":"100795","article-title":"Brief Report: Longitudinal tracking of ALK rearranged non-small cell lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA","volume":"6","author":"Heeke S","year":"2025","unstructured":"Heeke S, Gandhi S, Tran HT, et al: Brief Report: Longitudinal tracking of ALK rearranged non-small cell lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA. JTO Clin Res Rep 6:100795, 2025","journal-title":"JTO Clin Res Rep"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01121-2"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-00181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:59:12Z","timestamp":1750967952000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-00181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/PO-25-00181"],"URL":"https:\/\/doi.org\/10.1200\/po-25-00181","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2025-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500181"}}